2020
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. Patients
2019
Long term outcomes of sentinel lymph node biopsy for ductal carcinoma in situ
Hung P, Wang SY, Killelea BK, Mougalian SS, Evans SB, Sedghi T, Gross CP. Long term outcomes of sentinel lymph node biopsy for ductal carcinoma in situ. JNCI Cancer Spectrum 2019, 3: pkz052. PMID: 32337481, PMCID: PMC7049982, DOI: 10.1093/jncics/pkz052.Peer-Reviewed Original ResearchSentinel lymph node biopsyBreast-conserving surgeryBreast cancer mortalityLong-term outcomesDuctal carcinomaCancer mortalityEnd Results-Medicare datasetCompeting-risks survival analysisLymph node biopsyPopulation cohort dataNode biopsyOlder patientsSentinel lymphBreast conservationUS SurveillanceTerm outcomesSurvival analysisDCISPatientsStatistical significanceRoutine performanceBiopsySurgeryCarcinomaRecurrence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply